US OptionsDetailed Quotes
RIGL240920C12000
- 1.79
- +0.49+37.69%
15min DelayClose Sep 16 16:00 ET
1.79High1.79Low
1.79Open1.30Pre Close2 Volume32 Open Interest12.00Strike Price358.00Turnover90.63%IV0.29%PremiumSep 20, 2024Expiry Date1.75Intrinsic Value100Multiplier3DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.9390Delta0.0964Gamma7.68Leverage Ratio-0.0199Theta0.0011Rho7.21Eff Leverage0.0017Vega
Rigel Pharmaceuticals Stock Discussion
C'mon 14.+
Rigel to Present at the 2024 Cantor Global Healthcare Conference
just
Rigel Announces First Patient Enrolled in Phase 1B/2 Triplet Therapy Trial of Rezlidhia® (Olutasidenib) in Midh1 Aml
On September 3, 2024, Rigel Pharmaceuticals, Inc. (“Rigel”) entered into a collaboration and license agreement (the “License Agreement”) and a supply agreement (the “Supply Agreement”) with Kissei Pharmaceutical Co., Ltd. (“Kissei”). Pursuant to the terms of the License Agreement, Kissei received exclusive rights to develop and commercialize olutasidenib in all human diseases in Japan, the R...
13.88
Bring on 14.+
No comment yet